doi;PMID;section;ITC num;Ind studies num;questions;reviewer 1;reviewer 2;decision;identical;Notes reviewer 1;Notes reviewer 2
10.2217/cer.15.33;26159375;general_information;;;Medical Condition of Interest Name;chronic genotype 1b hepatitis c;genotype 1b hepatitis c virus infection;XXXX;FALSE;NA;NA
10.2217/cer.15.33;26159375;general_information;;;Countries of first author affiliations;;;usa;TRUE;;
10.2217/cer.15.33;26159375;general_information;;;Countries of last author affiliations;;;usa;TRUE;;
10.2217/cer.15.33;26159375;general_information;;;Positions of study investigators (for any authors of the article, any that applies);;;Pharmaceutical Industry, Private Data Analysis Company;TRUE;;
10.2217/cer.15.33;26159375;general_information;;;At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;general_information;;;Mentioned sources of funding;;;Pharmaceutical Industry;TRUE;;
10.2217/cer.15.33;26159375;general_information;;;Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;general_information;;;Mention of a systematic review to find the studies to compare treatments of interest;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;1;Patient-level data used;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;1;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;1;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT01497834;TRUE;;
10.2217/cer.15.33;26159375;study_information;;1;Country where the clinical trial/observational study was conducted (international if more than one);;;japan;TRUE;;
10.2217/cer.15.33;26159375;study_information;;1;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;1;Number of treatment arms (clinical trial only);;;1;TRUE;;
10.2217/cer.15.33;26159375;study_information;;10;Patient-level data used;;;No;TRUE;;
10.2217/cer.15.33;26159375;study_information;;10;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;10;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT01289782;TRUE;;
10.2217/cer.15.33;26159375;study_information;;10;Country where the clinical trial/observational study was conducted (international if more than one);;;international;TRUE;;
10.2217/cer.15.33;26159375;study_information;;10;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;10;Number of treatment arms (clinical trial only);;;2 or more;TRUE;;
10.2217/cer.15.33;26159375;study_information;;11;Patient-level data used;;;No;TRUE;;
10.2217/cer.15.33;26159375;study_information;;11;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;11;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT01290679;TRUE;;
10.2217/cer.15.33;26159375;study_information;;11;Country where the clinical trial/observational study was conducted (international if more than one);;;international;TRUE;;
10.2217/cer.15.33;26159375;study_information;;11;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;11;Number of treatment arms (clinical trial only);;;2 or more;TRUE;;
10.2217/cer.15.33;26159375;study_information;;12;Patient-level data used;;;No;TRUE;;
10.2217/cer.15.33;26159375;study_information;;12;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;12;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT01281839;TRUE;;
10.2217/cer.15.33;26159375;study_information;;12;Country where the clinical trial/observational study was conducted (international if more than one);;;international;TRUE;;
10.2217/cer.15.33;26159375;study_information;;12;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;12;Number of treatment arms (clinical trial only);;;2 or more;TRUE;;
10.2217/cer.15.33;26159375;study_information;;13;Patient-level data used;;;No;TRUE;;
10.2217/cer.15.33;26159375;study_information;;13;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;13;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT01641640;TRUE;;
10.2217/cer.15.33;26159375;study_information;;13;Country where the clinical trial/observational study was conducted (international if more than one);international;usa;XXXX;FALSE;;
10.2217/cer.15.33;26159375;study_information;;13;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;13;Number of treatment arms (clinical trial only);;;1;TRUE;;
10.2217/cer.15.33;26159375;study_information;;2;Patient-level data used;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;2;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;2;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT01581203;TRUE;;
10.2217/cer.15.33;26159375;study_information;;2;Country where the clinical trial/observational study was conducted (international if more than one);;;international;TRUE;;
10.2217/cer.15.33;26159375;study_information;;2;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;2;Number of treatment arms (clinical trial only);2 or more;1;2 or more;FALSE;;
10.2217/cer.15.33;26159375;study_information;;3;Patient-level data used;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;3;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;3;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT01718145;TRUE;;
10.2217/cer.15.33;26159375;study_information;;3;Country where the clinical trial/observational study was conducted (international if more than one);;;japan;TRUE;;
10.2217/cer.15.33;26159375;study_information;;3;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;3;Number of treatment arms (clinical trial only);;;2 or more;TRUE;;
10.2217/cer.15.33;26159375;study_information;;4;Patient-level data used;;;No;TRUE;;
10.2217/cer.15.33;26159375;study_information;;4;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;4;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT00627926;TRUE;;
10.2217/cer.15.33;26159375;study_information;;4;Country where the clinical trial/observational study was conducted (international if more than one);;;international;TRUE;;
10.2217/cer.15.33;26159375;study_information;;4;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;4;Number of treatment arms (clinical trial only);;;2 or more;TRUE;;
10.2217/cer.15.33;26159375;study_information;;5;Patient-level data used;;;No;TRUE;;
10.2217/cer.15.33;26159375;study_information;;5;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;5;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT01241760;TRUE;;
10.2217/cer.15.33;26159375;study_information;;5;Country where the clinical trial/observational study was conducted (international if more than one);;;international;TRUE;;
10.2217/cer.15.33;26159375;study_information;;5;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;5;Number of treatment arms (clinical trial only);1;2 or more;2 or more;FALSE;;
10.2217/cer.15.33;26159375;study_information;;6;Patient-level data used;;;No;TRUE;;
10.2217/cer.15.33;26159375;study_information;;6;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;6;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT00758043;TRUE;;
10.2217/cer.15.33;26159375;study_information;;6;Country where the clinical trial/observational study was conducted (international if more than one);;;international;TRUE;;
10.2217/cer.15.33;26159375;study_information;;6;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;6;Number of treatment arms (clinical trial only);1;2 or more;2 or more;FALSE;;
10.2217/cer.15.33;26159375;study_information;;7;Patient-level data used;;;No;TRUE;;
10.2217/cer.15.33;26159375;study_information;;7;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;7;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT00703118;TRUE;;
10.2217/cer.15.33;26159375;study_information;;7;Country where the clinical trial/observational study was conducted (international if more than one);;;international;TRUE;;
10.2217/cer.15.33;26159375;study_information;;7;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;7;Number of treatment arms (clinical trial only);;;2 or more;TRUE;;
10.2217/cer.15.33;26159375;study_information;;8;Patient-level data used;;;No;TRUE;;
10.2217/cer.15.33;26159375;study_information;;8;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;8;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT00705432;TRUE;;
10.2217/cer.15.33;26159375;study_information;;8;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;8;Number of treatment arms (clinical trial only);;;2 or more;TRUE;;
10.2217/cer.15.33;26159375;study_information;;8;Country where the clinical trial/observational study was conducted (international if more than one);unknown;;unknown;FALSE;;
10.2217/cer.15.33;26159375;study_information;;9;Patient-level data used;;;No;TRUE;;
10.2217/cer.15.33;26159375;study_information;;9;Clinical Trial;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;study_information;;9;NCT (only for clinical trial registered on clinicaltrials.gov);;;NCT00708500;TRUE;;
10.2217/cer.15.33;26159375;study_information;;9;Phase of the clinical trial (clinical trial only);;;3;TRUE;;
10.2217/cer.15.33;26159375;study_information;;9;Number of treatment arms (clinical trial only);2 or more;3 or more;2 or more;FALSE;;
10.2217/cer.15.33;26159375;study_information;;9;Country where the clinical trial/observational study was conducted (international if more than one);unknown;;international;FALSE;;
10.2217/cer.15.33;26159375;methodology;1;;Treatment name 1;;;daclatasvir + asunaprevir;TRUE;Supplemental materials unavailable   treatment naive patients;"Treatment-naive patients
N non IPD are taken from Table 2 (The sum of N in each arm)
No access to supplementary materials"
10.2217/cer.15.33;26159375;methodology;1;;Study 'number(s)' for treatment 1;;;"2;3";TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Treatment name 2;;;telaprevir + peginterferon-α + ribavirin;TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Study 'number(s)' for treatment 2;;;"4;5;6";TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Type of population-adjusted indirect comparisons performed;;;MAIC;TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Anchored comparison?;;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Form of the indirect comparison;;;Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate);TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Definition of a single primary outcome for the indirect comparison;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);sustained virologic response;proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment;sustained virologic response;FALSE;;
10.2217/cer.15.33;26159375;methodology;1;;Primary outcome: variable type;;;Binary (eg rates);TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Justification for selecting variables to be included in the adjustment model (in the main text);;;Nothing mentioned, not reported;TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Inclusion of prognostic factors in the adjustment/matching model;;;No discussion (in the main text) of the status of prognostic factors of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Inclusion of treatment-effect modifiers in the adjustment/matching model;;;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;1;;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Treatment name 1;;;daclatasvir + asunaprevir;TRUE;treatment naive patients;"Treatment-naive patients
N non IPD are taken from Table 2
No access to supplementary materials"
10.2217/cer.15.33;26159375;methodology;2;;Study 'number(s)' for treatment 1;;;"2;3";TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Treatment name 2;;;boceprevir + peginterferon-α + ribavirin;TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Study 'number(s)' for treatment 2;;;8;TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Type of population-adjusted indirect comparisons performed;;;MAIC;TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Anchored comparison?;;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Form of the indirect comparison;;;Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate);TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Definition of a single primary outcome for the indirect comparison;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);sustained virologic response;proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment;sustained virologic response;FALSE;;
10.2217/cer.15.33;26159375;methodology;2;;Primary outcome: variable type;;;Binary (eg rates);TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Justification for selecting variables to be included in the adjustment model (in the main text);;;Nothing mentioned, not reported;TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Inclusion of prognostic factors in the adjustment/matching model;;;No discussion (in the main text) of the status of prognostic factors of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Inclusion of treatment-effect modifiers in the adjustment/matching model;;;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;2;;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Treatment name 1;;;daclatasvir + asunaprevir;TRUE;treatment naive patients;"Treatment-naive patients
N non IPD are taken from Table 2 (The sum of N in each arm)
No access to supplementary materials"
10.2217/cer.15.33;26159375;methodology;3;;Study 'number(s)' for treatment 1;;;"2;3";TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Treatment name 2;;;simeprevir + peginterferon-α + ribavirin;TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Study 'number(s)' for treatment 2;;;"10;11";TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Type of population-adjusted indirect comparisons performed;;;MAIC;TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Anchored comparison?;;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Form of the indirect comparison;;;Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate);TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Definition of a single primary outcome for the indirect comparison;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);sustained virologic response;proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment;sustained virologic response;FALSE;;
10.2217/cer.15.33;26159375;methodology;3;;Primary outcome: variable type;;;Binary (eg rates);TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Justification for selecting variables to be included in the adjustment model (in the main text);;;Nothing mentioned, not reported;TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Inclusion of prognostic factors in the adjustment/matching model;;;No discussion (in the main text) of the status of prognostic factors of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Inclusion of treatment-effect modifiers in the adjustment/matching model;;;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;3;;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Treatment name 1;;;daclatasvir + asunaprevir;TRUE;treatment naive patients;"Treatment-naive patients
N non IPD are taken from Table 2
No access to supplementary materials"
10.2217/cer.15.33;26159375;methodology;4;;Study 'number(s)' for treatment 1;;;"2;3";TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Treatment name 2;;;sofosbuvir + peginterferon-α + ribavirin;TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Study 'number(s)' for treatment 2;;;13;TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Type of population-adjusted indirect comparisons performed;;;MAIC;TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Anchored comparison?;;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Form of the indirect comparison;;;Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate);TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Definition of a single primary outcome for the indirect comparison;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);sustained virologic response;proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment;sustained virologic response;FALSE;;
10.2217/cer.15.33;26159375;methodology;4;;Primary outcome: variable type;;;Binary (eg rates);TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Justification for selecting variables to be included in the adjustment model (in the main text);;;Nothing mentioned, not reported;TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Inclusion of prognostic factors in the adjustment/matching model;;;No discussion (in the main text) of the status of prognostic factors of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Inclusion of treatment-effect modifiers in the adjustment/matching model;;;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;4;;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Treatment name 1;;;daclatasvir + asunaprevir;TRUE;treatment naive patients;"Treatment-naive patients
N non IPD are taken from Table 2 (The sum of N in each arm)
No access to supplementary materials"
10.2217/cer.15.33;26159375;methodology;5;;Study 'number(s)' for treatment 1;;;"2;3";TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Treatment name 2;;;peginterferon-α + ribavirin;TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Study 'number(s)' for treatment 2;;;"4;8;10;11";TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Type of population-adjusted indirect comparisons performed;;;MAIC;TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Anchored comparison?;;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Form of the indirect comparison;;;Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate);TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Definition of a single primary outcome for the indirect comparison;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);sustained virologic response;proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment;sustained virologic response;FALSE;;
10.2217/cer.15.33;26159375;methodology;5;;Primary outcome: variable type;;;Binary (eg rates);TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Justification for selecting variables to be included in the adjustment model (in the main text);;;Nothing mentioned, not reported;TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Inclusion of prognostic factors in the adjustment/matching model;;;No discussion (in the main text) of the status of prognostic factors of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Inclusion of treatment-effect modifiers in the adjustment/matching model;;;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;5;;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Treatment name 1;;;daclatasvir + asunaprevir;TRUE;treatment experienced patients;"Treatment-experienced patients
N non IPD are taken from Table 2
No access to supplementary materials"
10.2217/cer.15.33;26159375;methodology;6;;Study 'number(s)' for treatment 1;;;"1;2;3";TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Treatment name 2;;;telaprevir + peginterferon-α + ribavirin;TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Study 'number(s)' for treatment 2;;;7;TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Type of population-adjusted indirect comparisons performed;;;MAIC;TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Anchored comparison?;;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Form of the indirect comparison;;;Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate);TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Definition of a single primary outcome for the indirect comparison;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);sustained virologic response;proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment;sustained virologic response;FALSE;;
10.2217/cer.15.33;26159375;methodology;6;;Primary outcome: variable type;;;Binary (eg rates);TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Justification for selecting variables to be included in the adjustment model (in the main text);;;Nothing mentioned, not reported;TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Inclusion of prognostic factors in the adjustment/matching model;;;No discussion (in the main text) of the status of prognostic factors of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Inclusion of treatment-effect modifiers in the adjustment/matching model;;;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;6;;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Treatment name 1;;;daclatasvir + asunaprevir;TRUE;treatment experienced patients;"Treatment-experienced patients
N non IPD are taken from Table 2
No access to supplementary materials"
10.2217/cer.15.33;26159375;methodology;7;;Study 'number(s)' for treatment 1;;;"1;2;3";TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Treatment name 2;;;boceprevir + peginterferon-α + ribavirin;TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Study 'number(s)' for treatment 2;;;9;TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Type of population-adjusted indirect comparisons performed;;;MAIC;TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Anchored comparison?;;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Form of the indirect comparison;;;Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate);TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Definition of a single primary outcome for the indirect comparison;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);sustained virologic response;proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment;sustained virologic response;FALSE;;
10.2217/cer.15.33;26159375;methodology;7;;Primary outcome: variable type;;;Binary (eg rates);TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Justification for selecting variables to be included in the adjustment model (in the main text);;;Nothing mentioned, not reported;TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Inclusion of prognostic factors in the adjustment/matching model;;;No discussion (in the main text) of the status of prognostic factors of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Inclusion of treatment-effect modifiers in the adjustment/matching model;;;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;7;;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Treatment name 1;;;daclatasvir + asunaprevir;TRUE;treatment experienced patients;"Treatment-experienced patients
N non IPD are taken from Table 2
No access to supplementary materials"
10.2217/cer.15.33;26159375;methodology;8;;Study 'number(s)' for treatment 1;;;"1;2;3";TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Treatment name 2;;;simeprevir + peginterferon-α + ribavirin;TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Study 'number(s)' for treatment 2;;;12;TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Type of population-adjusted indirect comparisons performed;;;MAIC;TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Anchored comparison?;;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Form of the indirect comparison;;;Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate);TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Definition of a single primary outcome for the indirect comparison;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);sustained virologic response;proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment;sustained virologic response;FALSE;;
10.2217/cer.15.33;26159375;methodology;8;;Primary outcome: variable type;;;Binary (eg rates);TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Justification for selecting variables to be included in the adjustment model (in the main text);;;Nothing mentioned, not reported;TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Inclusion of prognostic factors in the adjustment/matching model;;;No discussion (in the main text) of the status of prognostic factors of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Inclusion of treatment-effect modifiers in the adjustment/matching model;;;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;8;;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Treatment name 1;;;daclatasvir + asunaprevir;TRUE;treatment experienced patients;"Treatment-experienced patients
N non IPD are taken from Table 2 (The sum of N in each arm)
No access to supplementary materials"
10.2217/cer.15.33;26159375;methodology;9;;Study 'number(s)' for treatment 1;;;"1;2;3";TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Treatment name 2;;;peginterferon-α + ribavirin;TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Study 'number(s)' for treatment 2;;;"9;12";TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Type of population-adjusted indirect comparisons performed;;;MAIC;TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Anchored comparison?;;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Form of the indirect comparison;;;Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate);TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Definition of a single primary outcome for the indirect comparison;;;Yes;TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined);sustained virologic response;proportion of genotype 1b patients achieving svr at week 12 or week 24 post-treatment;sustained virologic response;FALSE;;
10.2217/cer.15.33;26159375;methodology;9;;Primary outcome: variable type;;;Binary (eg rates);TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Justification for selecting variables to be included in the adjustment model (in the main text);;;Nothing mentioned, not reported;TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Inclusion of prognostic factors in the adjustment/matching model;;;No discussion (in the main text) of the status of prognostic factors of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Inclusion of treatment-effect modifiers in the adjustment/matching model;;;No discussion (in the main text) of the status of treatment-effect modifiers of the variables;TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc);;;No;TRUE;;
10.2217/cer.15.33;26159375;methodology;9;;Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale);;;No;TRUE;;
10.2217/cer.15.33;26159375;results;1;;Sample size of the population of interest in the non IPD treatment arm;1643;1630;1643;FALSE;;
10.2217/cer.15.33;26159375;results;1;;Reporting of a weights' distribution evaluation (MAIC);;;Not mentioned;TRUE;;
10.2217/cer.15.33;26159375;results;1;;Reporting of the list of the covariates adjusted for/matched on;;;No;TRUE;;
10.2217/cer.15.33;26159375;results;1;;Primary outcome: treatment effect contrast;;;Rate difference;TRUE;;
10.2217/cer.15.33;26159375;results;1;;Direction of the treatment effect contrast: IPD treatment is:;;;Numerator if ratio, or left side if difference;TRUE;;
10.2217/cer.15.33;26159375;results;1;;Primary outcome: adjusted treatment effect;;;8.7;TRUE;;
10.2217/cer.15.33;26159375;results;1;;"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[0.2;17.3]";"[0.2;17.3] p<0.05";"[0.2;17.3]";FALSE;;
10.2217/cer.15.33;26159375;results;1;;Initial sample size of the population of interest in the IPD treatment arm;324;;324;FALSE;;
10.2217/cer.15.33;26159375;results;2;;Sample size of the population of interest in the non IPD treatment arm;;;368;TRUE;;
10.2217/cer.15.33;26159375;results;2;;Reporting of a weights' distribution evaluation (MAIC);;;Not mentioned;TRUE;;
10.2217/cer.15.33;26159375;results;2;;Reporting of the list of the covariates adjusted for/matched on;;;No;TRUE;;
10.2217/cer.15.33;26159375;results;2;;Primary outcome: treatment effect contrast;;;Rate difference;TRUE;;
10.2217/cer.15.33;26159375;results;2;;Direction of the treatment effect contrast: IPD treatment is:;;;Numerator if ratio, or left side if difference;TRUE;;
10.2217/cer.15.33;26159375;results;2;;Primary outcome: adjusted treatment effect;;;16.5;TRUE;;
10.2217/cer.15.33;26159375;results;2;;"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[2.5;30.5]";"[2.5;30.5] p<0.05";"[2.5;30.5]";FALSE;;
10.2217/cer.15.33;26159375;results;2;;Initial sample size of the population of interest in the IPD treatment arm;324;;324;FALSE;;
10.2217/cer.15.33;26159375;results;3;;Sample size of the population of interest in the non IPD treatment arm;;;521;TRUE;;
10.2217/cer.15.33;26159375;results;3;;Reporting of a weights' distribution evaluation (MAIC);;;Not mentioned;TRUE;;
10.2217/cer.15.33;26159375;results;3;;Reporting of the list of the covariates adjusted for/matched on;;;No;TRUE;;
10.2217/cer.15.33;26159375;results;3;;Primary outcome: treatment effect contrast;;;Rate difference;TRUE;;
10.2217/cer.15.33;26159375;results;3;;Direction of the treatment effect contrast: IPD treatment is:;;;Numerator if ratio, or left side if difference;TRUE;;
10.2217/cer.15.33;26159375;results;3;;Primary outcome: adjusted treatment effect;;;0.4;TRUE;;
10.2217/cer.15.33;26159375;results;3;;"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";;;"[-8.9;9.7]";TRUE;;
10.2217/cer.15.33;26159375;results;3;;If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm;NA;;XXXX;FALSE;;
10.2217/cer.15.33;26159375;results;3;;Initial sample size of the population of interest in the IPD treatment arm;324;;324;FALSE;;
10.2217/cer.15.33;26159375;results;4;;Sample size of the population of interest in the non IPD treatment arm;;;327;TRUE;;
10.2217/cer.15.33;26159375;results;4;;Reporting of a weights' distribution evaluation (MAIC);;;Not mentioned;TRUE;;
10.2217/cer.15.33;26159375;results;4;;Reporting of the list of the covariates adjusted for/matched on;;;No;TRUE;;
10.2217/cer.15.33;26159375;results;4;;Primary outcome: treatment effect contrast;;;Rate difference;TRUE;;
10.2217/cer.15.33;26159375;results;4;;Direction of the treatment effect contrast: IPD treatment is:;;;Numerator if ratio, or left side if difference;TRUE;;
10.2217/cer.15.33;26159375;results;4;;Primary outcome: adjusted treatment effect;;;3;TRUE;;
10.2217/cer.15.33;26159375;results;4;;"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";;;"[-21.2;27.1]";TRUE;;
10.2217/cer.15.33;26159375;results;4;;Initial sample size of the population of interest in the IPD treatment arm;324;;324;FALSE;;
10.2217/cer.15.33;26159375;results;5;;Sample size of the population of interest in the non IPD treatment arm;;;988;TRUE;;
10.2217/cer.15.33;26159375;results;5;;Reporting of a weights' distribution evaluation (MAIC);;;Not mentioned;TRUE;;
10.2217/cer.15.33;26159375;results;5;;Reporting of the list of the covariates adjusted for/matched on;;;No;TRUE;;
10.2217/cer.15.33;26159375;results;5;;Primary outcome: treatment effect contrast;;;Rate difference;TRUE;;
10.2217/cer.15.33;26159375;results;5;;Direction of the treatment effect contrast: IPD treatment is:;;;Numerator if ratio, or left side if difference;TRUE;;
10.2217/cer.15.33;26159375;results;5;;Primary outcome: adjusted treatment effect;;;39.6;TRUE;;
10.2217/cer.15.33;26159375;results;5;;"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[30.3;48.9]";"[30.3;48.9] p<0.05";"[30.3;48.9]";FALSE;;
10.2217/cer.15.33;26159375;results;5;;Initial sample size of the population of interest in the IPD treatment arm;324;;324;FALSE;;
10.2217/cer.15.33;26159375;results;6;;Sample size of the population of interest in the non IPD treatment arm;540;266;266;FALSE;;
10.2217/cer.15.33;26159375;results;6;;"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC";;NA;XXXX;FALSE;;
10.2217/cer.15.33;26159375;results;6;;Reporting of a weights' distribution evaluation (MAIC);;;Not mentioned;TRUE;;
10.2217/cer.15.33;26159375;results;6;;Reporting of the list of the covariates adjusted for/matched on;;;No;TRUE;;
10.2217/cer.15.33;26159375;results;6;;Primary outcome: treatment effect contrast;;;Rate difference;TRUE;;
10.2217/cer.15.33;26159375;results;6;;Direction of the treatment effect contrast: IPD treatment is:;;;Numerator if ratio, or left side if difference;TRUE;;
10.2217/cer.15.33;26159375;results;6;;Primary outcome: adjusted treatment effect;;;17;TRUE;;
10.2217/cer.15.33;26159375;results;6;;"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[5.3;28.7]";"[5.3;28.7] p<0.05";"[5.3;28.7]";FALSE;;
10.2217/cer.15.33;26159375;results;6;;Initial sample size of the population of interest in the IPD treatment arm;314;;314;FALSE;;
10.2217/cer.15.33;26159375;results;7;;Sample size of the population of interest in the non IPD treatment arm;;;162;TRUE;;
10.2217/cer.15.33;26159375;results;7;;Reporting of a weights' distribution evaluation (MAIC);;;Not mentioned;TRUE;;
10.2217/cer.15.33;26159375;results;7;;Reporting of the list of the covariates adjusted for/matched on;;;No;TRUE;;
10.2217/cer.15.33;26159375;results;7;;Primary outcome: treatment effect contrast;;;Rate difference;TRUE;;
10.2217/cer.15.33;26159375;results;7;;Direction of the treatment effect contrast: IPD treatment is:;;;Numerator if ratio, or left side if difference;TRUE;;
10.2217/cer.15.33;26159375;results;7;;Primary outcome: adjusted treatment effect;;;22.8;TRUE;;
10.2217/cer.15.33;26159375;results;7;;"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[6.9;38.7]";"[6.9;38.7] p<0.05";"[6.9;38.7]";FALSE;;
10.2217/cer.15.33;26159375;results;7;;Initial sample size of the population of interest in the IPD treatment arm;314;;314;FALSE;;
10.2217/cer.15.33;26159375;results;8;;Sample size of the population of interest in the non IPD treatment arm;;;260;TRUE;;
10.2217/cer.15.33;26159375;results;8;;Reporting of a weights' distribution evaluation (MAIC);;;Not mentioned;TRUE;;
10.2217/cer.15.33;26159375;results;8;;Reporting of the list of the covariates adjusted for/matched on;;;No;TRUE;;
10.2217/cer.15.33;26159375;results;8;;Primary outcome: treatment effect contrast;;;Rate difference;TRUE;;
10.2217/cer.15.33;26159375;results;8;;Direction of the treatment effect contrast: IPD treatment is:;;;Numerator if ratio, or left side if difference;TRUE;;
10.2217/cer.15.33;26159375;results;8;;Primary outcome: adjusted treatment effect;;;10.3;TRUE;;
10.2217/cer.15.33;26159375;results;8;;"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[1.1;19.5]";"[1.1;19.5] p<0.05";"[1.1;19.5]";FALSE;;
10.2217/cer.15.33;26159375;results;8;;Initial sample size of the population of interest in the IPD treatment arm;314;;314;FALSE;;
10.2217/cer.15.33;26159375;results;9;;Sample size of the population of interest in the non IPD treatment arm;;;213;TRUE;;
10.2217/cer.15.33;26159375;results;9;;Reporting of a weights' distribution evaluation (MAIC);;;Not mentioned;TRUE;;
10.2217/cer.15.33;26159375;results;9;;Reporting of the list of the covariates adjusted for/matched on;;;No;TRUE;;
10.2217/cer.15.33;26159375;results;9;;Primary outcome: treatment effect contrast;;;Rate difference;TRUE;;
10.2217/cer.15.33;26159375;results;9;;Direction of the treatment effect contrast: IPD treatment is:;;;Numerator if ratio, or left side if difference;TRUE;;
10.2217/cer.15.33;26159375;results;9;;Primary outcome: adjusted treatment effect;;;57.7;TRUE;;
10.2217/cer.15.33;26159375;results;9;;"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])";"[44.0;71.4]";"[44.0;71.4] p<0.05";"[44.0;71.4]";FALSE;;
10.2217/cer.15.33;26159375;results;9;;Initial sample size of the population of interest in the IPD treatment arm;314;;314;FALSE;;
